<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04672850</url>
  </required_header>
  <id_info>
    <org_study_id>Prozicold</org_study_id>
    <nct_id>NCT04672850</nct_id>
  </id_info>
  <brief_title>The Effect of Probiotic and Zinc Supplementation on the Common Cold</brief_title>
  <official_title>The Effect of Probiotic and Zinc Supplementation on the Common Cold in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lund University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Coradil AB</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Lund University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose with this study is to investigate the preventative effect of a supplement&#xD;
      containing a combination of probiotic bacteria and fungi as well as zinc on the common cold.&#xD;
      The hypothesis is that it will shorten the duration, alleviate the severity of symptoms or&#xD;
      even decrease the number of infectons during the intervention period. This study is a&#xD;
      randomzed placebo controlled human study were healthy adults will consume the supplement for&#xD;
      three months.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">January 27, 2021</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double-blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Symptoms severity</measure>
    <time_frame>Three months</time_frame>
    <description>Decrease in the severity of symptoms will be determined using a common cold questionnaire.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composition of gut and oral microbiome</measure>
    <time_frame>Three months</time_frame>
    <description>Change in gut and oral microbiome will be measured using 16SrRNA and 18SrRNA sequencing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IgA</measure>
    <time_frame>Three months</time_frame>
    <description>Changes in levels of IgA in saliva and/or feces will be measured using ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of symptoms</measure>
    <time_frame>Three months</time_frame>
    <description>Decrease in duration of cold will be determined using a common cold questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of colds</measure>
    <time_frame>Three months</time_frame>
    <description>Decrease in number of colds will be determined using a common cold questionnaire</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Common Cold</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Rice flour</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Probiotic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Probiotic bacteria, yeast, zinc and rice brand</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Probiotic</intervention_name>
    <description>The participants will consume 2 capsules daily for three months</description>
    <arm_group_label>Probiotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The participants will consume 2 capsules daily for three months</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy adults&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosed gastrointestinal disorders&#xD;
&#xD;
          -  Autoimmune diseases or immuno compromized&#xD;
&#xD;
          -  Antibiotic treatment in the last month&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Lunds universitet</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>December 3, 2020</study_first_submitted>
  <study_first_submitted_qc>December 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 17, 2020</study_first_posted>
  <last_update_submitted>February 9, 2021</last_update_submitted>
  <last_update_submitted_qc>February 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Lund University</investigator_affiliation>
    <investigator_full_name>Åsa Håkansson</investigator_full_name>
    <investigator_title>Assoc. Prof.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Common Cold</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Only group data will be shared</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

